- Home
- KPTI vs CMU Comparison
KPTI vs CMU Comparison
Compare KPTI & CMU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- CMU
- Stock Information
- Founded
- KPTI 2008
- CMU 1987
- Country
- KPTI United States
- CMU United States
- Employees
- KPTI N/A
- CMU N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- CMU Investment Managers
- Sector
- KPTI Health Care
- CMU Finance
- Exchange
- KPTI Nasdaq
- CMU Nasdaq
- Market Cap
- KPTI 90.7M
- CMU 89.6M
- IPO Year
- KPTI 2013
- CMU N/A
- Fundamental
- Price
- KPTI $0.62
- CMU $3.54
- Analyst Decision
- KPTI Strong Buy
- CMU
- Analyst Count
- KPTI 4
- CMU 0
- Target Price
- KPTI $5.00
- CMU N/A
- AVG Volume (30 Days)
- KPTI 676.1K
- CMU 82.4K
- Earning Date
- KPTI 02-27-2025
- CMU 01-01-0001
- Dividend Yield
- KPTI N/A
- CMU 4.08%
- EPS Growth
- KPTI N/A
- CMU N/A
- EPS
- KPTI N/A
- CMU 0.07
- Revenue
- KPTI $148,442,000.00
- CMU N/A
- Revenue This Year
- KPTI $5.47
- CMU N/A
- Revenue Next Year
- KPTI $6.33
- CMU N/A
- P/E Ratio
- KPTI N/A
- CMU $47.57
- Revenue Growth
- KPTI 1.77
- CMU N/A
- 52 Week Low
- KPTI $0.58
- CMU $2.78
- 52 Week High
- KPTI $1.95
- CMU $3.38
- Technical
- Relative Strength Index (RSI)
- KPTI 40.06
- CMU 51.48
- Support Level
- KPTI $0.65
- CMU $3.50
- Resistance Level
- KPTI $0.70
- CMU $3.53
- Average True Range (ATR)
- KPTI 0.05
- CMU 0.03
- MACD
- KPTI -0.00
- CMU 0.01
- Stochastic Oscillator
- KPTI 11.00
- CMU 71.43
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About CMU MFS Municipal Income Trust
Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes.